Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Avalon GloboCare (ALBT) Research & Development (2018 - 2023)

Avalon GloboCare (ALBT) has 6 years of Research & Development data on record, last reported at -$542.0 in Q4 2023.

  • For Q4 2023, Research & Development rose 99.86% year-over-year to -$542.0; the TTM value through Dec 2023 reached $109618.0, down 30.72%, while the annual FY2023 figure was $109618.0, 30.72% down from the prior year.
  • Research & Development reached -$542.0 in Q4 2023 per ALBT's latest filing, down from $17810.0 in the prior quarter.
  • Across five years, Research & Development topped out at $949711.0 in Q2 2019 and bottomed at -$383338.0 in Q4 2022.
  • Average Research & Development over 5 years is $208346.3, with a median of $213188.0 recorded in 2021.
  • Peak YoY movement for Research & Development: surged 361006.84% in 2019, then tumbled 209.85% in 2022.
  • A 5-year view of Research & Development shows it stood at $414559.0 in 2019, then crashed by 49.6% to $208920.0 in 2020, then skyrocketed by 67.03% to $348956.0 in 2021, then crashed by 209.85% to -$383338.0 in 2022, then skyrocketed by 99.86% to -$542.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Research & Development were -$542.0 in Q4 2023, $17810.0 in Q2 2023, and $92350.0 in Q1 2023.